Every Form 4 that Flora Growth Corp. (FLGC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow FLGC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FLGC filings page.
ZeroStack Corp. director Laurence Zeifman reported a compensation-related award of options to buy 28,000 Common Shares. These director stock options have an exercise price of $5.10 per share and were granted at no cost.
The options vest in three equal installments: one-third on May 5, 2026, one-third on August 30, 2026, and one-third on December 31, 2026. Following this award, Zeifman holds 28,000 director stock options directly, with an expiration date of May 4, 2036.
ZeroStack Corp. director Edward Woo reported a compensation-related stock option grant on Common Shares. He received a Director Stock Option covering 35,000 shares, with an exercise price of $5.10 per share and an expiration date of May 4, 2036. Following this grant, he holds derivative rights over 35,000 shares directly. The options vest in three equal installments: one-third on May 5, 2026, one-third on August 30, 2026, and one-third on December 31, 2026. This Form 4 reflects an award acquisition rather than an open-market purchase or sale.
ZeroStack Corp. director Manfred Leventhal received a grant of 35,000 stock options. These Director Stock Options give him the right to buy 35,000 common shares at an exercise price of $5.10 per share and expire on May 4, 2036.
The options vest in three equal installments: one-third on May 5, 2026, one-third on August 30, 2026, and one-third on December 31, 2026. After this grant, he holds 35,000 options directly, reflecting a compensation award rather than an open-market trade.
ZeroStack Corp. Executive Chairman Heinrich Michael reported an "other" restructuring transaction involving a convertible promissory note held indirectly through Zero Gravity Labs Inc., a corporation he owns and controls. The note was tied to 4,902,220 common shares at a conversion price of $33.34 per share and had an expiration date in September 2035. A note settlement agreement provides that payment of 50,000,000 Tokens to Zero Gravity Labs Inc. fully satisfies the principal and interest, leaving no further obligations under the note and no remaining derivative holdings from this instrument.
Flora Growth Corp. (FLGC) disclosed that Executive Chairman and Director Michael Heinrich filed a Form 4 reporting an indirect derivative position. A convertible promissory note held through Zero Gravity Labs Inc., which he owns and controls, is convertible into up to 4,902,220 common shares at a $33.34 conversion price per share. The note became exercisable on October 23, 2025 and expires on September 22, 2035, with conversion at the holder’s option after shareholder approval on October 22, 2025.
The reported 4,902,220 shares comprise 4,499,100 shares underlying principal and 403,120 shares underlying interest through September 2026. Following the transaction, the filing lists 4,902,220 derivative securities beneficially owned, held indirectly via Zero Gravity Labs Inc.
Flora Growth Corp. (FLGC) reported a director equity award. Director Michael John Brown acquired 7,468 Deferred Share Units (DSUs) on 10/22/2025, shown at a derivative security price of $0. Following the transaction, he beneficially owned 94,421 derivative securities. Each DSU represents the right to receive one common share after his service as a director ends. For U.S. participants, settlement occurs 6 months after the termination date; for non‑U.S. participants, settlement occurs on the 20th business day after the termination date. Ownership is reported as Direct.
Flora Growth Corp. CEO and director Daniel Reis-Faria reported a transaction dated 10/09/2025 showing acquisition of 5,954,743 pre-funded token warrants. The filing lists the warrant exercise price as $0.0001 and shows the underlying common shares amount as 5,954,743 with a price column of $25.1899. The filing notes the warrants are not exercisable until approved by the issuer's shareholders and will terminate upon full exercise. The Form 4 was signed on 10/10/2025. This report documents an insider's sizeable beneficial position subject to shareholder approval before conversion.